LIMITATION AND ADVANCE IN THE DEVELOPMENT OF ORODISPERSIBLE FILMS FOR DRUG DELIVERY
DOI:
https://doi.org/10.22159/ijap.2026v18i1.56232Keywords:
Orodispersible films (ODFs), Personalized medicine, Bioavailability, Patient Compliance, PolymerAbstract
Orodispersible films (ODFs) are increasingly recognized as an important innovation in drug delivery, as they offer quick disintegration, better bioavailability, and greater comfort for patients. They are especially beneficial for children, the elderly, and those who have challenging in swallowing, since ODFs dissolve in the mouth and allow drugs to be absorbed through a sublingual or buccal route, avoiding metabolism by the liver. This review discusses the development of ODFs in detail, including formulation strategies, manufacturing methods, the current market landscape, and limitations that still affect these systems. The discussion incorporates significant details from an extensive review of recently published papers and patents on the subject, focusing on material screening, design considerations, and production processes. The review discusses physicochemical properties, stability issues, regulatory considerations, and challenges associated with industrial production, typically from pharmaceutical and engineering perspectives. While a number of advances have been made, challenges such as limited drug load and stability issues, and product scale-up still remain. This article attempts to identify these gaps to suggest areas for future research to improve performance, scale-up and commercialisation to enable ODFs for patients in need of products other than a conventional dosage form.
References
1. Guo B, Sofias AM, Lammers T, Xu J. Image-guided drug delivery: nanoparticle and probe advances. Adv Drug Deliv Rev. 2024;206:115188. doi: 10.1016/j.addr.2024.115188, PMID 38272185.
2. Rathod A, Sonawane M, Pawar K, Nikam V, Tamboli A. Innovative drug delivery system oral fast dissolving film: a comprehensive review. RJPDFT. 2025;17(2):149-63. doi: 10.52711/0975-4377.2025.00022.
3. Zaki RM, Alfadhel M, Devanatha Desikan Seshadri VD, Albagami F, Alrobaian M, Tawati SM. Fabrication and characterization of orodispersible films loaded with solid dispersion to enhance rosuvastatin calcium bioavailability. Saudi Pharm J. 2022;31(1):135-46. doi: 10.1016/j.jsps.2022.11.012, PMID 36685296.
4. Garsuch V, Breitkreutz J. Novel analytical methods for the characterization of oral wafers. Eur J Pharm Biopharm. 2009;73(1):195-201. doi: 10.1016/j.ejpb.2009.05.010, PMID 19482082.
5. Hoffmann EM, Breitenbach A, Breitkreutz J. Advances in orodispersible films for drug delivery. Expert Opin Drug Deliv. 2011;8(3):299-316. doi: 10.1517/17425247.2011.553217, PMID 21284577.
6. Jacob S, Boddu SH, Bhandare R, Ahmad SS, Nair AB. Orodispersible films: current innovations and emerging trends. Pharmaceutics. 2023;15(12):2753. doi: 10.3390/pharmaceutics15122753, PMID 38140094.
7. Sharma R, Joshi D, Singh B, Semwal N. A review on orodispersible film a novel approach of drug delivery system. World J Bio Pharm Health Sci. 2022;12(1):1-11. doi: 10.30574/wjbphs.2022.12.1.0130.
8. Chen F, Liu H, Wang B, Yang L, Cai W, Jiao Z. Physiologically based pharmacokinetic modeling to understand the absorption of risperidone orodispersible film. Front Pharmacol. 2020;10:1692. doi: 10.3389/fphar.2019.01692, PMID 32116683.
9. He M, Zhu L, Yang N, Li H, Yang Q. Recent advances of oral film as platform for drug delivery. Int J Pharm. 2021;604:120759. doi: 10.1016/j.ijpharm.2021.120759, PMID 34098053.
10. Borges AF, Silva C, Coelho JF, Simoes S. Oral films: current status and future perspectives: I Galenical development and quality attributes. J Control Release. 2015;206:1-19. doi: 10.1016/j.jconrel.2015.03.006, PMID 25747406.
11. Straits Research. Oral thin films market size share and demand by 2033. Report Code SRHI3641DR. 2025 May. p. 110. Available from: https://straitsresearch.com/report/oral-thin-films-market. [Last accessed on 07 Oct 2025].
12. Badekar R, Bodke V, Tekade BW, Phalak SD. An overview on oral thin films-methodology characterization and current approach. Int J Pharm Pharm Sci. 2024;16(4):1-10. doi: 10.22159/ijpps.2024v16i4.50386.
13. Cupone IE, Sansone A, Marra F, Giori AM, Jannini EA. Orodispersible film (ODF) platform based on maltodextrin for therapeutical applications. Pharmaceutics. 2022;14(10):2011. doi: 10.3390/pharmaceutics14102011, PMID 36297447.
14. Ruchika KN, Khan N, Dogra SS, Saneja A. The dawning era of oral thin films for nutraceutical delivery: from laboratory to clinic. Biotechnol Adv. 2024;73:108362. doi: 10.1016/j.biotechadv.2024.108362, PMID 38615985.
15. Musazzi UM, Khalid GM, Selmin F, Minghetti P, Cilurzo F. Trends in the production methods of orodispersible films. Int J Pharm. 2020;576:118963. doi: 10.1016/j.ijpharm.2019.118963, PMID 31857185.
16. Ferlak J, Guzenda W, Osmalek T. Orodispersible films-current state of the art, limitations advances and future perspectives. Pharmaceutics. 2023;15(2):361. doi: 10.3390/pharmaceutics15020361, PMID 36839683.
17. Li Y, Zhao M, Zhao MY, Li B, Tian JL. Advances in oral dissolving film research in the food field. Food Prod Process and Nutr. 2025;7(1):1-15. doi: 10.1186/s43014-024-00285-X.
18. Palezi SC, Fernandes SS, Martins VG. Oral disintegration films: applications and production methods. J Food Sci Technol. 2022 Sep;60(10):2539-48. doi: 10.1007/s13197-022-05589-9, PMID 37599841.
19. Khalid GM, Selmin F, Musazzi UM, Gennari CG, Minghetti P, Cilurzo F. Trends in the characterization methods of orodispersible films. Curr Drug Deliv. 2021;18(7):935-46. doi: 10.2174/1567201818999201210212557, PMID 33305704.
20. Singh Rawat B, Badola A, Kumar Rajput S, Semalty A, Kumar R, Pandey S. A review on orodispersible film-based novel drug delivery system. Res J Pharm Technol. 2024;17(7):3480-8. doi: 10.52711/0974-360X.2024.00544.
21. Banerjee S, Joshi U, Singh A, Saharan VA. Lipids for taste masking and taste assessment in pharmaceutical formulations. Chem Phys Lipids. 2021;235:105031. doi: 10.1016/j.chemphyslip.2020.105031, PMID 33352198.
22. Sannala CK, Mac Lean C, Larsen F, Van OS S, Jadhav P, Shore N. A model-informed drug development approach to design a phase 3 trial of teverelix drug product in advanced prostate cancer patients with increased cardiovascular risk. Clin Pharmacol Drug Dev. 2024;13(8):915-29. doi: 10.1002/cpdd.1415, PMID 38757461.
23. Tian Y, Lin J, Jing H, Wang Q, Wu Z, Duan Y. Recent progress in orodispersible films-mediated therapeutic applications: a review. Med Comm. 2023;2(2):e1034. doi: 10.1002/mba2.34.
24. Sinha S, Sonali, Garg V, Thapa S, Singh S, Chauhan M. Empagliflozin containing chitosan-alginate nanoparticles in orodispersible film: preparation, characterization pharmacokinetic evaluation and its in vitro anticancer activity. Drug Dev Ind Pharm. 2022;48(7):279-91. doi: 10.1080/03639045.2022.2108829, PMID 35913103.
25. Pacheco MS, Barbieri D, Da Silva CF, De Moraes MA. A review on orally disintegrating films (ODFs) made from natural polymers such as pullulan, maltodextrin starch and others. Int J Biol Macromol. 2021 May 1;178:504-13. doi: 10.1016/j.ijbiomac.2021.02.180, PMID 33647337.
26. Mishra A, Pathak AK. Plasticizers: a vital excipient in novel pharmaceutical formulations. Curr Res Pharm Sci. 2017 May;7(1):1-10. doi: 10.24092/CRPS.2017.070101.
27. Abdelkader H, Abdel Aleem JA, Mousa HS, Elgendy MO, Al Fatease A, Abou-Taleb HA. Captopril polyvinyl alcohol/sodium alginate/gelatin-based oral dispersible films (ODFs) with modified release and advanced oral bioavailability for the treatment of pediatric hypertension. Pharmaceuticals (Basel). 2023;16(9):1323. doi: 10.3390/ph16091323, PMID 37765131.
28. Chen K, Sun Y. Development and optimization of oral dissolution films for enhanced delivery of ebastine-loaded solid lipid nanoparticles. Int J Nanomedicine. 2025;20:6963-81. doi: 10.2147/IJN.S521504, PMID 40462833.
29. Suksawat T, Brniak W, Lyszczarz E, Wesoly M, Ciosek Skibinska P, Mendyk A. Orodispersible dosage forms with Rhinacanthin rich extract as a convenient formulation dedicated to pediatric patients. Pharmaceuticals (Basel). 2024;17(8):994. doi: 10.3390/ph17080994, PMID 39204099.
30. Wang C, Li Z, Zhai H, Shen X, Li F, Zhang Q. Targeted blocking of EGFR and GLUT1 by compound H reveals a new strategy for treatment of triple-negative breast cancer and nasopharyngeal carcinoma. Eur J Pharm Sci. 2024;198:106789. doi: 10.1016/j.ejps.2024.106789, PMID 38710335.
31. Liew KB, Tan YT, Peh KK. Effect of polymer plasticizer and filler on orally disintegrating film. Drug Dev Ind Pharm. 2014;40(1):110-9. doi: 10.3109/03639045.2012.749889, PMID 23311593.
32. Olechno K, Basa A, Winnicka K. “Success depends on your backbone”-about the use of polymers as essential materials forming orodispersible films. Materials (Basel). 2021;14(17):4872. doi: 10.3390/ma14174872, PMID 34500962.
33. Kandil H, El Desouky FG. Plasticizer modulation of dynamic mechanical properties and dielectric performance in sodium alginate-based biopolymer films. J Inorg Organomet Polym. 2025;35(7):5790-804. doi: 10.1007/s10904-025-03623-9.
34. Mathur S, Bulchandan N, Parihar S, Shekhawat GS. Critical review on steviol glycosides: pharmacological toxicological and therapeutic aspects of high potency zero caloric sweetener. Int J Pharmacol. 2017;13(7):916-28. doi: 10.3923/ijp.2017.916.928.
35. Peteliuk V, Rybchuk L, Bayliak M, Storey KB, Lushchak O. Natural sweetener Stevia rebaudiana: functionalities, health benefits and potential risks. Excli J. 2021;20:1412-30. doi: 10.17179/excli2021-4211, PMID 34803554.
36. Maharjan S, Adhikari S, KC N, Dura S, Manandhar M. Formulation and evaluation of ondansetron oral dispersible tablet using different natural disintegrants. AJAST. 2021;5(4):82-92. doi: 10.38177/ajast.2021.5410.
37. Mitchell H. Sweeteners and sugar alternatives in food technology. 2nd ed. Oxford: Wiley-Blackwell; 2007. doi: 10.1002/9780470996003.
38. Pezik E, Gulsun T, Sahin S, Vural I. Development and characterization of pullulan-based orally disintegrating films containing amlodipine besylate. Eur J Pharm Sci. 2021;156:105597. doi: 10.1016/j.ejps.2020.105597, PMID 33065224.
39. El Bary AA, Al Sharabi I, Haza A BS. Effect of casting solvent film-forming agent and solubilizer on orodispersible films of a polymorphic poorly soluble drug: an in vitro/in silico study. Drug Dev Ind Pharm. 2019;45(11):1751-69. doi: 10.1080/03639045.2019.1656733, PMID 31416366.
40. Manda P, Popescu C, Juluri A, Janga K, Kakulamarri PR, Narishetty S. Micronized zaleplon delivery via orodispersible film and orodispersible tablets. AAPS PharmSciTech. 2018;19(3):1358-66. doi: 10.1208/s12249-017-0924-9, PMID 29352403.
41. Singh N, Sweta S, Jindal S. A concise overview on orodispersible film along with their formulation and characterization technique’s. RJPDFT. 2024;16(1):98-106. doi: 10.52711/0975-4377.2024.00016.
42. Jannini EA, Vignesh SO, Hassan T. Next-generation pharmaceuticals: the rise of sildenafil citrate ODF for the treatment of men with erectile dysfunction. Ther Deliv. 2025;16(4):365-78. doi: 10.1080/20415990.2024.2445501, PMID 39801170.
43. Speer I, Preis M, Breitkreutz J. Prolonged drug release properties for orodispersible films by combining hot-melt extrusion and solvent casting methods. Eur J Pharm Biopharm. 2018;129:66-73. doi: 10.1016/j.ejpb.2018.05.023, PMID 29792911.
44. Reuther M, Rollet N, Debeaufort F, Chambin O. Orodispersible films prepared by hot-melt extrusion versus solvent casting. Int J Pharm. 2025;675:125536. doi: 10.1016/j.ijpharm.2025.125536, PMID 40164416.
45. Trinh TH, Tran HT. Processing from natural products to effective pharmaceutical drugs: involvement of hot melt extrusion technique. Nat Prod Res. 2025;39(1):1-24. doi: 10.1080/14786419.2025.2538096, PMID 40729595.
46. Zhang J, Sun X, Shao R, Liang W, Gao J, Chen J. Polycation liposomes combined with calcium phosphate nanoparticles as a non-viral carrier for siRNA delivery. J Drug Deliv Sci Technol. 2015;30:1-6. doi: 10.1016/j.jddst.2015.09.005.
47. Kang D, Kim J, Kim I, Choi KH, Lee TM. Experimental qualification of the process of electrostatic spray deposition. Coatings. 2019;9(5):294. doi: 10.3390/coatings9050294, PMID 31721973.
48. Lai W, Di L, Zhao C, Tian Y, Duan Y, Pan Y. Electrospray deposition for electronic thin films on 3D freeform surfaces: from mechanisms to applications. Adv Materials Technologies. 2024;9:2400192. doi: 10.1002/admt.202400192.
49. Salawi A. An insight into preparatory methods and characterization of orodispersible film-a review. Pharmaceuticals (Basel). 2022;15(7):844. doi: 10.3390/ph15070844, PMID 35890143.
50. Madapally VD, Pandima Devi M. Fabrication of nanofibres by electrospinning using keratin from waste chicken feathers PVA and AgNPs. Int J Pharm Pharm Sci. 2019;11(8):78-84. doi: 10.22159/ijpps.2019v11i8.33637.
51. Wang P, Li Y, Zhang C, Feng F, Zhang H. Sequential electrospinning of multilayer ethylcellulose/gelatin/ethylcellulose nanofibrous film for sustained release of curcumin. Food Chem. 2020;308:125599. doi: 10.1016/j.foodchem.2019.125599, PMID 31648098.
52. Misra R, Fung G, Sharma S, Hu J, Kirkitadze M. Assessment of tunable resistive pulse sensing (TRPS) technology for particle size distribution in vaccine formulations a comparative study with dynamic light scattering. Pharm Res. 2024;41(5):1021-9. doi: 10.1007/s11095-024-03698-y, PMID 38649535.
53. Luraghi A, Peri F, Moroni L. Electrospinning for drug delivery applications: a review. J Control Release. 2021;334:463-84. doi: 10.1016/j.jconrel.2021.03.033, PMID 33781809.
54. Garcia Astrain C, Ahmed S, Pavon E, Smyth M, Larraneta E. 3D printed mucoadhesive orodispersible films loaded with nanocrystals for enhanced delivery of poorly soluble drugs. Addit Manuf. 2024;82:104038. doi: 10.1016/j.addma.2024.104038.
55. Steiner D, Tidau M, Finke JH. Embedding of poorly water-soluble drugs in orodispersible films-comparison of five formulation strategies. Pharmaceutics. 2022;15(1):17. doi: 10.3390/pharmaceutics15010017, PMID 36678646.
56. Muehlenfeld C, Duffy P, Yang F, Zermeno Perez D, El Saleh F, Durig T. Excipients in pharmaceutical additive manufacturing: a comprehensive exploration of polymeric material selection for enhanced 3D printing. Pharmaceutics. 2024;16(3):317. doi: 10.3390/pharmaceutics16030317, PMID 38543211.
57. Elbl J, Racaniello GF, Simon MC. Development of 3D printed multi-layered orodispersible films for personalized drug delivery. Drug Deliv Transl Res. 2023;13(4):1234-45. doi: 10.1007/s13346-023-01045-6, PMID 36912345.
58. Kuril A, Ambekar A, Nimase B, Giri P, Nikam P, Desai H. Exploring the potential of 3D printing in pharmaceutical development. Int J Curr Pharm Sci. 2023;15(6):31-42. doi: 10.22159/ijcpr.2023v15i6.3085.
59. Borges AF, Silva C, Coelho JF, Simões S. Oral films: current status and future perspectives II intellectual property technologies and market needs. J Control Release. 2015;206:108-21. doi: 10.1016/j.jconrel.2015.03.012, PMID 25776737.
60. Costa JS. A mini-review on drug delivery through wafer technology. Int J Pharm. 2019;558:178-90. doi: 10.1016/j.ijpharm.2019.01.031.
61. Ahmed SU, Gorukanti SR, Chowdhury TA; Barr Laboratories Inc. Assignee. Ondansetron orally disintegrating tablets. US Patent US7390503B2; 2008 Jun 24.
62. US Food and Drug Administration. Guidelines for the conduct of an in vivo bioavailability study. Washington, DC: U.S. Government Publishing Office; 2021. Available https://www.law.cornell.edu/cfr/text/21/320.25. [Last accessed on 07 Oct 2025].
63. European Medicines Agency. ICH M13A guideline on bioequivalence for immediate-release solid oral dosage forms. In: Amsterdam: European Medicines Agency; 2024. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m13a-guideline-bioequivalence-immediate-release-solid-oral-dosage-forms_en.pdf. [Last accessed on 07 Oct 2025].
64. Sullivan JG, Webster L. Novel buccal film formulation of buprenorphine naloxone for the maintenance treatment of opioid dependence: a 12 w conversion study. Clin Ther. 2015;37(5):1064-75. doi: 10.1016/j.clinthera.2015.02.027, PMID 25823919.
65. Pinal R. Enhancing the bioavailability of poorly soluble drugs. Pharmaceutics. 2024;16(6):758. doi: 10.3390/pharmaceutics16060758, PMID 38931880.
66. European Medicines Agency. ICH. In: Stability testing of new drug substances and drug products-scientific guideline. Vol. Q1A(R2). London, UK: European Medicines Agency; 2003. Available from: https://www.ema.europa.eu/en/ich-q1a-r2-stability-testing-new-drug-substances-drug-products-scientific-guideline. [Last accessed on 07 Oct 2025].
Published
How to Cite
Issue
Section
Copyright (c) 2026 B. MUKESH, M. DHIYANESHWARAN, C. GOKUL KUMAR, N. SHABARISHA, M. V. SARANYA, G. RAMYA, K. THAMARAISELVI, ARUN RADHAKRISHNAN
This work is licensed under a Creative Commons Attribution 4.0 International License.